Genetic variants in immunoregulatory genes and risk for childhood lymphomas

European Journal of Haematology

Volumn 83, Issue 4, 2009, Pages 334-342

  Andrie, Elisabeth ^a   Michos, Athanasios ^b   Kalampoki, Vassiliki ^a   Pourtsidis, Apostolos ^c   Moschovi, Maria ^a   Polychronopoulou, Sophia ^d   Athanasiadou Piperopoulou, Fani ^e   Kalmanti, Maria ^f   Hatzakis, Angelos ^a   Paraskevis, Dimitrios ^a   Nieters, Alexandra ^g   Petridou, Eleni Th ^a,h  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c Department of Pediatric Hematology Oncology   (Greece)

^d Aghia Sophia General Children's Hospital Athens   (Greece)

^e ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^f UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Childhood lymphoma; Cytokine; Polymorphisms; Th1 Th2

Indexed keywords

CD14 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HODGKIN DISEASE; HUMAN; IMMUNOREGULATION; INFANT; INNATE IMMUNITY; MALE; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; REGULATOR GENE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ANTIGENS, CD14; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; GENOTYPE; HODGKIN DISEASE; HUMANS; IMMUNITY; INFANT; LYMPHOMA; LYMPHOMA, NON-HODGKIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 70349136206     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01288.x     Document Type: Article

References (49)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW, ed. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC Press, 2001.
2. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002 99 : 4283 4297.
3. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006 107 : 4101 4108.
4. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996 9 : 532 562.
5. Hofmann SR, Ettinger R, Zhou YJ, Gadina M, Lipsky P, Siegel R, Candotti F, O'Shea JJ. Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr Opin Allergy Clin Immunol 2002 2 : 495 506.
6. Kurzrock R. Cytokine deregulation in hematological malignancies: clinical and biological implications. Clin Cancer Res 1997 3 : 2581 2584.
7. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006 7 : 27 38.
8. Howell WM, Rose-Zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 2007 137 : 194S 9S.
9. Seidemann K, Zimmermann M, Book M, Meyer U, Burkhardt B, Welte K, Reiter A, Stanulla M. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Munster Trial NHL-BFM 95. J Clin Oncol 2005 23 : 8414 8421.
10. Petridou E, Klimentopoulou AE, Moustaki M, Kostrikis LG, Hatzakis A, Trichopoulos D. Recent thymic emigrants and prognosis in T- and B-cell childhood hematopoietic malignancies. Int J Cancer 2002 101 : 74 7.
11. Nieters A, Brems S, Becker N. Cross-sectional study on cytokine polymorphisms, cytokine production after T-cell stimulation and clinical parameters in a random sample of a German population. Hum Genet 2001 108 : 241 248.
12. Nakayama EE, Hoshino Y, Xin X, et al. Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol 2000 74 : 5452 5459.
13. Olavesen MG, Hampe J, Mirza MM, et al. Analysis of single-nucleotide polymorphisms in the interleukin-4 receptor gene for association with inflammatory bowel disease. Immunogenetics 2000 51 : 1 7.
14. Linker-Israeli M, Wallace DJ, Prehn J, Michael D, Honda M, Taylor KD, Paul-Labrador M, Fischel-Ghodsian N, Fraser PA, Klinenberg JR. Association of IL-6 gene alleles with systemic lupus erythematosus (SLE) and with elevated IL-6 expression. Genes Immun 1999 1 : 45 52.
15. Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol 1999 7 : 127 128.
16. Hall MA, McGlinn E, Coakley G, et al. Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun 2000 1 : 219 224.
17. Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 2001 112 : 146 152.
18. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 2000 61 : 863 866.
19. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A Polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999 20 : 976 983.
20. Arias MA, Rey Nores JE, Vita N, Stelter F, Borysiewicz LK, Ferrara P, Labéta MO. Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production. J Immunol 2000 164 : 3480 3486.
21. Endo S, Inada K, Kasai T, Takakuwa T, Nakae H, Kikuchi M, Yamashita H, Yoshida M. Soluble CD14 (sCD14) levels in patients with multiple organ failure (MOF). Res Commun Chem Pathol Pharmacol 1994 84 : 17 25.
22. Kruger C, Schutt C, Obertacke U, Joka T, Muller FE, Knoller J, Köller M, König W, Schönfeld W. Serum CD14 levels in polytraumatized and severely burned patients. Clin Exp Immunol 1991 85 : 297 301.
23. Baseggio L, Charlot C, Picollet J, Bienvenu J, Salles G. High circulating tumor necrosis factor levels correlate with increased evels of soluble CD14 in patients with non-Hodgkin's lymphoma. Haematologica 2001 86 : 774 775.
24. Hohaus S, Giachelia M, Di Febo A, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma. Ann Oncol 2007 18 : 1376 1381.
25. Yoshimoto T, Tsutsui H, Tominaga K, Hoshino K, Okamura H, Akira S, Paul WE, Nakanishi K. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A 1999 96 : 13962 13966.
26. Rodriguez-Galan MC, Bream JH, Farr A, Young HA. Synergistic effect of IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1/Th2 cytokine expression. J Immunol 2005 174 : 2796 2804.
27. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Ann Rev Immunol 2001 19 : 423 474.
28. Kretowski A, Mironczuk K, Karpinska A, Bojaryn U, Kinalski M, Puchalski Z, Kinalska I. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes 2002 51 : 3347 3349.
29. Tamura K, Fukuda Y, Sashio H, et al. IL18 polymorphism is associated with an increased risk of Crohn's disease. J Gastroenterol 2002 37 : 111 116.
30. Hajeer AH, Hutchinson IV. TNF-a gene polymorphism: clinical and biological implications. Microsc Res Tech 2000 50 : 216 228.
31. Cerhan JR, Liu-Mares W, Fredericksen ZS, et al. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2008 17 : 3161 3169.
32. Bel Hadj Jrad B, Chatti A, Laatiri A, Ahmed SB, Romdhane A, Ajimi S, Chouchane L. Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin's lymphomas. Eur J Haematol 2007 78 : 117 122.
33. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, Whitby D, Chanock S, Rothman N, Armstrong BK. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 2007 28 : 704 712.
34. Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, Chatterjee N, Yeager M, Chanock SJ, Rothman N, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 2006 66 : 9771 9780.
35. Wang SS, Cozen W, Cerhan JR, et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 2007 67 : 5042 5054.
36. Spink CF, Keen LJ, Mensah FK, Law GR, Bidwell JL, Morgan GJ. Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol 2006 133 : 293 300.
37. Juszczynski P, Kalinka E, Bienvenu J, et al. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 2002 100 : 3037 3040.
38. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, Coiffier B, Salles G. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998 91 : 3574 3581.
39. Wihlborg C, Sjöberg J, Intaglietta M, Axdorph U, Pisa EK, Pisa P. Tumour necrosis factor-alpha cytokine promoter gene polymorphism in Hodgkin's disease and chronic lymphocytic leukaemia. Br J Haematol 1999 104 : 346 349.
40. Morahan G, Huang D, Wu M, Holt BJ, White GP, Kendall GE, Sly PD, Holt PG. Association of IL12B promoter polymorphism with severity of atopic and non-atopic asthma in children. Lancet 2002 360 : 455 459.
41. Malec M, Soderqvist M, Sirsjo A, MacNamara B, Lewin N, Sjoberg J, Björkholm M, Porwit-MacDonald A. Real-time polymerase chain reaction determination of cytokine mRNA expression profiles in Hodgkin's lymphoma. Haematologica 2004 89 : 679 685.
42. Kabesch M, Tzotcheva I, Carr D, Höfler C, Weiland K, Fritzsch C, von Mutius E, Martinez FD. A complete screening of the IL4 gene: novel polymorphisms and their association with asthma and IgE in childhood. J Allergy Clin Immunol 2003 112 : 893 898.
43. Cordano P, Lake A, Shield L, Taylor GM, Alexander FE, Taylor PR, White J, Jarrett RF. Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin's lymphoma. Br J Haematol 2005 128 : 493 495.
44. Cozen W, Gill PS, Ingles SA, et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood 2004 103 : 3216 3221.
45. Munro LR, Johnston PW, Marshall NA, Canning SJ, Hewitt SG, Tveita K, Vickers MA. Polymorphisms in the interleukin-10 and interferon gamma genes in Hodgkin lymphoma. Leuk Lymphoma 2003 44 : 2083 2088.
46. Bogunia-Kubik K, Mazur G, Wróbel T, Kuliczkowski K, Lange A. Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. Tissue Antigens 2008 71 : 146 150.
47. Lech-Maranda E, Baseggio L, Charlot C, Rigal D, Berger F, Jamroziak K, Warzocha K, Coiffier B, Salles G. Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. Leuk Lymphoma 2007 48 : 2235 2238.
48. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Warzocha K, Coiffier B, Salles G. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004 103 : 3529 3534.
49. Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJ. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2003 44 : 251 255.